HAYWARD, Calif., March 7, 2012 /PRNewswire/ -- Solta Medical,
Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics
market, today provided an update on the launch of the second
generation Liposonix non-invasive fat reduction system recently
approved by the FDA.
A majority of the Company's approximately twenty key opinion
leaders (KOLs), comprised of leading plastic surgeons and
dermatologists, who received Liposonix systems in mid-December as
part of the pre-launch trial, have successfully evaluated and
purchased the product. The company expects that virtually all the
remaining KOL's evaluating the system will purchase the device this
month. Liposonix was officially introduced in early January of
2012.
"For the full year 2012, we provided guidance that we would
generate approximately $17 million in
Liposonix revenue," said Stephen J.
Fanning, Chairman, President and CEO of Solta Medical.
"Through the first two months of the year, we are on track to meet
or exceed this guidance. Systems have been sold, on average, at
list price."
The Liposonix system uses non-invasive, high-intensity focused
ultrasound (or HIFU) to permanently get rid of targeted fat around
the waistline, love handles and abdomen, without surgery. The
average waistline reduction after just one, 1-hour treatment is
about one inch – which typically means one dress or pant size.
Results are usually seen in 8 to 12 weeks (which is the time needed
for the body to naturally remove the treated fat).
Since its introduction, Liposonix has been featured in many high
profile media outlets, including national broadcast programs such
as Dr. Oz, The Doctors, and 20/20 with Barbara Walters. Thus far the Liposonix
treatment has received very positive reviews from patients as
reflected in on-line aesthetic procedure forums.
"The Gen 2 system is proving to provide several distinct
advantages compared with the first generation, including a larger
treatment tip, which enables clinicians to deliver comparable
energy over multiple passes while maintaining a treatment time of
about an hour," continued Mr. Fanning. "This has improved the
treatment experience for both patients and physicians."
"In addition, most physicians using Liposonix do not find it
necessary to medicate patients for the treatment, and those that
do, are using non-narcotic medication, resulting in little to no
post-treatment downtime. The acceptance and feedback from
physicians about our Gen 2 system has been extremely positive and
Liposonix is delivering on its promise of one treatment, one hour,
one inch or pant size smaller," Mr. Fanning concluded.
The Company will be exhibiting Liposonix along with all of its
industry leading aesthetic solutions at the American Academy of
Dermatology meeting from March 17 to
19 at the San Diego
Convention Center (Booth #1211).
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics
market providing innovative, safe, and effective solutions for
patients that enhance and expand the practice of medical aesthetics
for physicians. The company offers products to address a range of
skin issues under the industry´s six premier brands: Thermage®,
Fraxel®, Liposonix®, Isolaz®, CLARO® and Clear + Brilliant®.
Thermage is an innovative, non-invasive radiofrequency procedure
for tightening and contouring skin. As the leader in fractional
laser technology, Fraxel delivers minimally invasive clinical
solutions to resurface aging and sun damaged skin. The Liposonix
system uses advanced high–intensity focused ultrasound (HIFU)
technology to permanently destroy targeted fat just beneath the
skin in the treatment areas of the abdomen and flanks as a
noninvasive, nonsurgical approach to aesthetic waist circumference
reduction. Isolaz was the first laser or light based system
indicated for the treatment of inflammatory acne, comedonal acne,
pustular acne, and mild–to–moderate inflammatory acne. CLARO is a
personal care acne system that is the first FDA cleared
over–the–counter IPL device that uses a powerful combination of
both heat and light to clear skin quickly and naturally. Clear +
Brilliant is a unique, cost–effective treatment that utilizes safe,
fractional laser technology to correct and prevent early signs of
aging and is FDA cleared and CE marked. Since 2002, over one
million Thermage, Fraxel and Isolaz procedures have been performed
in over 100 countries. For more information about Solta Medical,
call 1-877-782-2286 or log on to www.Solta.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995, including statements regarding expected future purchases of
Liposonix systems and anticipated revenue. Forward-looking
statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties, which may
cause Solta Medical's actual results to differ materially from the
statements contained herein. Factors that might cause such a
difference include the risk that physician adoption of our systems
does not grow, the risk that customers do not continue to purchase
treatment tips, the possibility that the market for the sale of new
products does not develop as expected, and the risks relating to
Solta Medical's ability to achieve its stated financial goals as a
result of, among other things, economic conditions and consumer and
physician confidence causing changes in consumer and physician
spending habits that affect demand for our products and treatments.
Further information on potential risk factors that could affect
Solta Medical's business and its financial results are detailed in
its Form 10-Q for the quarter ended September 30, 2011, and other reports as filed
from time to time with the Securities and Exchange Commission.
Undue reliance should not be placed on forward-looking statements,
especially guidance on future financial performance, which speaks
only as of the date they are made. Solta Medical undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
they were made, or to reflect the occurrence of unanticipated
events.
SOURCE Solta Medical, Inc.